Immunotherapy for the treatment of drug abuse

Kosten, T. and Owens, S. M. (2005) Immunotherapy for the treatment of drug abuse. Pharmacology and Therapeutics, 108 1: 76-85. doi:10.1016/j.pharmthera.2005.06.009

Author Kosten, T.
Owens, S. M.
Title Immunotherapy for the treatment of drug abuse
Journal name Pharmacology and Therapeutics   Check publisher's open access policy
ISSN 0163-7258
Publication date 2005-10
Sub-type Critical review of research, literature review, critical commentary
DOI 10.1016/j.pharmthera.2005.06.009
Volume 108
Issue 1
Start page 76
End page 85
Total pages 10
Place of publication Philadelphia, PA, U.S.A.
Publisher Elsevier
Language eng
Subject 1115 Pharmacology and Pharmaceutical Sciences
Abstract Antibody therapy (as either active or passive immunization) is designed primarily to prevent drugs of abuse from entering the central nervous system (CNS). Antidrug antibodies reduce rush, euphoria, and drug distribution to the brain at doses that exceed the apparent binding capacity of the antibody. This is accomplished through a pharmacokinetic antagonism, which reduces the amount of drug in the brain, the rate of clearance across the blood-brain barrier, and the volume of drug distribution. Because the antibodies remain primarily in the circulatory system, they have no apparent central nervous system side effects. Active immunization with drug-protein conjugate vaccines has been tested for cocaine, heroin, methamphetamine, and nicotine in animal, with 1 cocaine and 3 nicotine vaccines in Phase 2 human trials. Passive immunization with high affinity monoclonal antibodies has been tested for cocaine, methamphetamine, nicotine, and phencyclidine (PCP) in preclinical animal models. Antibodies have 2 immediate clinical applications in drug abuse treatment: to treat drug overdose and to reduce relapse to drug use in addicted patients. The specificity of the therapies, the lack of addiction liability, minimal side effects, and long-lasting protection against drug use offer major therapeutic benefit over conventional small molecule agonists and antagonists. Immunotherapies can also be combined with other antiaddiction medications and enhance behavioral therapies. Current immunotherapies already show efficacy, but improved antigen design and antibody engineering promise highly specific and rapidly developed treatments for both existing and future addictions.
Keyword Drug abuse
Clinical trials
Drug dependence
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ
Additional Notes Issue title: Discovery, Development and Implementation of Novel Pharmacotherapies for Addiction

Document type: Journal Article
Sub-type: Critical review of research, literature review, critical commentary
Collections: ERA 2012 Admin Only
School of Public Health Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 73 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 84 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Thu, 28 Aug 2008, 17:42:26 EST